SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3% - Here's What Happened

Key Points

• SELLAS stock rose 10.3% to $3.8160 on Monday, with about 4.4 million shares traded — roughly 76% below its average daily volume of ~18.1 million.
• Analyst sentiment is mixed: Weiss Ratings reiterated a "sell (d-)," while MarketBeat shows one Buy and one Sell for an average "Hold" rating and an average price target of $7.00.
• Insider buying: director Katherine Bach Kalin purchased 63,400 shares at $1.59 (increasing her stake by 154.6%), and the company remains a clinical‑stage biotech (lead candidate galinpepimut‑S targeting WT1) with a market cap of about $585 million.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was up 10.3% on Monday . The stock traded as high as $3.76 and last traded at $3.8160. Approximately 4,401,928 shares were traded during trading, a decline of 76% from the average daily volume of 18,068,063 shares. The stock had previously closed at $3.46.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, SELLAS Life Sciences Group has an average rating of "Hold" and an average price target of $7.00.

SELLAS Life Sciences Group Price Performance

The firm's 50 day moving average price is $2.25 and its 200-day moving average price is $1.98. The stock has a market cap of $585.44 million, a P/E ratio of -14.68 and a beta of 2.26.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. On average, analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Insider Buying and Selling at SELLAS Life Sciences Group

In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin purchased 63,400 shares of the stock in a transaction dated Wednesday, November 19th. The shares were purchased at an average cost of $1.59 per share, with a total value of $100,806.00. Following the completion of the acquisition, the director directly owned 104,400 shares in the company, valued at $165,996. This trade represents a 154.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently modified their holdings of SLS. SG Americas Securities LLC increased its position in SELLAS Life Sciences Group by 88.2% during the fourth quarter. SG Americas Securities LLC now owns 36,450 shares of the company's stock valued at $137,000 after acquiring an additional 17,084 shares during the last quarter. Dagco Inc. purchased a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at about $2,177,000. Everhart Financial Group Inc. lifted its stake in shares of SELLAS Life Sciences Group by 40.8% in the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company's stock worth $1,758,000 after purchasing an additional 135,066 shares during the period. Bank of America Corp DE boosted its holdings in shares of SELLAS Life Sciences Group by 21.9% in the third quarter. Bank of America Corp DE now owns 42,150 shares of the company's stock worth $68,000 after buying an additional 7,571 shares during the last quarter. Finally, Anson Funds Management LP boosted its holdings in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company's stock worth $9,713,000 after buying an additional 5,757,938 shares during the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.